Please login to the form below
Synairgen
This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.
WHO to test three more potential COVID-19 treatments
Hydroxychloroquine and lopinavir/ritonavir (AbbVie’s Kaletra) are not being used currently, while UK-based biotech Synairgen has an ongoing trial investigating an inhaled formulation of Interferon-beta-1a in
Latest news
-
UK biotech Synairgen treats first patient in phase 3 COVID-19 trial
UK biotech company Synairgen has treated the first patient in a phase 3 trial evaluating its potential COVID-19 treatment SNG001. ... where vaccines become less effective,” said Richard Marsden, chief executive officer of Synairgen.
-
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. ... response. Initially, Synairgen had been evaluating the drug as a treatment for
-
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
UK-based biotech Synairgen has revealed positive data for its inhaled drug SNG001 in chronic obstructive pulmonary disease (COPD) patients, results which the company says supports its use in a separate ... treatment in the coming virus season, where
-
UK biotech Synairgen reveals promising early results for COVID-19 drug
Results from a phase 1 trial of Synairgen’s lead COVID-19 candidate SNG001 demonstrated a significant reduction in the risk of developing severe disease compared to placebo. ... Synairgen found that treatment with its drug resulted in a 79% lower risk
-
UK biotech Synairgen to begin COVID-19 trial of lead candidate
Southampton, UK-based biotech company Synairgen has been granted the go-ahead to take its lead candidate SNG001 into a trial for the treatment of COVID-19 patients. ... It’s fantastic to see a small UK biotech company, Synairgen starting UK clinical
More from news
Approximately 7 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
As the intense efforts to find a solution to COVID-19 finally start to bear fruit – with, for example, Synairgen showing promising results with SNG001 – how we’ve got here through ... in late March, when AIM-listed and Southampton-based Synairgen
-
Deal Watch table for June 2014
252. Synairgen/ AstraZeneca. Exclusive global licence. SNG 001 inhaled beta interferon (p2).
-
Pharma deals during June 2014
Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
